Johnson & Johnson (JNJ) 106.59 $JNJ
Jim Cramer's 'Mad Money' Recap: How to Invest in a Slowing World Economy
at The Street - 1 hr 20 mins ago
Shares of those companies that benefit from lower commodity prices such as restaurants, retail and apparel can still head higher.
Johnson & Johnson (JNJ) to Acquire Alios BioPharma - Stocks in the News
Zacks Research Staff - Zacks Investment Research - 1 hr 44 mins ago
JNJ stock is in focus after the company moves to acquire Alios BioPharma.
Ireland Exporters Look To Thursday's ECB Policy Vote
at Investor's Business Daily - Tue Sep 30, 5:24PM CDT
As the eurozone awaits a key announcement from the European Central Bank, and as the dollar caps its powerful third-quarter advance vs. the euro, Ireland's economy this month reported its Q2 GDP surged 7.7% -- its best performance since 2007. The...
Final Glance: Medical Devices companies
AP - Tue Sep 30, 5:04PM CDT
NEW YORK (AP) — Shares of some top medical devices companies were mixed at the close of trading:
Final Glance: Pharmaceuticals companies
AP - Tue Sep 30, 5:04PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
Stocks Move To Session Lows; Regeneron Rises On Drug Data
at Investor's Business Daily - Tue Sep 30, 2:04PM CDT
Major stock indexes nursed modest losses but were near session lows in late-afternoon trading Tuesday. The Nasdaq and S&P 500 each lost 0.4%, while the Dow Jones industrial average lost 0.3%. NYSE and Nasdaq volume was tracking about 15%-20% higher...
Defective Surgical Product Lawsuits Filed Against Johnson & Johnson
Business Wire - Tue Sep 30, 1:21PM CDT
Johnson & Johnson has been accused of knowingly developing and marketing a defective medical device known as Prolene(R) mesh used in hernia surgery in a series of lawsuits filed in New Jersey Superior Court. The latest, Jacky Pettigrew v. Johnson & Johnson et al., was filed today, according to plaintiffs' co-counsel Theodore J. Leopold of Cohen Milstein Sellers & Toll PLLC.
Midday Glance: Pharmaceuticals companies
AP - Tue Sep 30, 12:20PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Midday Glance: Medical Devices companies
AP - Tue Sep 30, 12:20PM CDT
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 1 p.m.:
Valeant's Bausch + Lomb Announces Results on Lotemax - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 30, 11:10AM CDT
Valeant Pharmaceuticals International, Inc. (VRX) announced that its wholly owned subsidiary, Bausch + Lomb, released positive results from a phase III study on Lotemax.
J&J Buying Alios, Going Up Against Gilead
at Investor's Business Daily - Tue Sep 30, 11:02AM CDT
Medical giant Johnson & Johnson agreed to buy privately held biotech Alios BioPharma for $1.75 billion Tuesday, advancing its presence in viral diseases. Johnson & Johnson (JNJ) stock was up a fraction in morning trading on the stock market today. In...
Early Glance: Medical Devices companies
AP - Tue Sep 30, 9:41AM CDT
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 10 a.m.:
Early Glance: Pharmaceuticals companies
AP - Tue Sep 30, 9:41AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
Johnson & Johnson buying Alios for $1.75B
AP - Tue Sep 30, 9:03AM CDT
NEW BRUNSWICK, N.J. (AP) — Johnson & Johnson is buying the biopharmaceutical company Alios BioPharma Inc. for about $1.75 billion.
Why J&J Expands Antiviral Franchise but Doesn't Buy Achillion, Novavax
at The Street - Tue Sep 30, 8:49AM CDT
What are the motivations behind significant takeovers, like J&J's takeover of Alios Biopharma? And why have companies like Achillion and Novavax been passed over?
How Will Johnson & Johnson (JNJ) Stock Be Affected by This Acquisition?
at The Street - Tue Sep 30, 8:34AM CDT
Johnson & Johnson shares are climbing after the company announced that it acquired Alios BioPharma for $1.75 billion in cash.
Gilead Sciences, Inc. Stock's Stunning New Opportunity
Cheryl Swanson, The Motley Fool - Motley Fool - Tue Sep 30, 8:15AM CDT
Call it Gilead Sciences ' stealth play. Gilead is the king of the HIV business. Its wildly successful Sovaldi launch is without a doubt the biggest biotech event of the year. But the company's experimental cancer drug pipeline is a different...
Cintas Beats on Q1 Earnings with Robust Margin Expansion - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 30, 8:00AM CDT
Cintas (CTAS) reported first-quarter fiscal 2015 adjusted earnings of 78 cents per share versus 62 cents in the year-ago quarter, beating the Zacks Consensus Estimate of 76 cents per share.
Alios BioPharma Announces Acquisition Agreement With Johnson & Johnson
Marketwire - Tue Sep 30, 7:30AM CDT
Alios BioPharma, Inc., a biotechnology company developing proprietary therapeutics for viral diseases, today announced a definitive agreement with Johnson & Johnson whereby Alios will be acquired for approximately $1.75 billion in cash payable upon closing of the transaction. The transaction has been approved by the boards of directors of both companies.
Johnson & Johnson Announces Agreement To Acquire Alios BioPharma
PR Newswire - Tue Sep 30, 7:30AM CDT
Johnson & Johnson (NYSE: JNJ) today announced a definitive agreement to acquire Alios BioPharma, Inc., a privately held clinical stage biopharmaceutical company focused on developing therapies for viral diseases, for approximately $1.75 billion in cash. The acquisition will include Alios BioPharma's portfolio of potential therapeutics for viral infections including compound AL-8176, an orally administered antiviral therapy currently in Phase 2 studies for the treatment of infants with respiratory syncytial virus (RSV).
Jim Cramer's 'Mad Money' Recap: How to Invest in a Slowing World Economy
at The Street - 1 hr 20 mins ago
Shares of those companies that benefit from lower commodity prices such as restaurants, retail and apparel can still head higher.
Johnson & Johnson (JNJ) to Acquire Alios BioPharma - Stocks in the News
Zacks Research Staff - Zacks Investment Research - 1 hr 44 mins ago
JNJ stock is in focus after the company moves to acquire Alios BioPharma.
Ireland Exporters Look To Thursday's ECB Policy Vote
at Investor's Business Daily - Tue Sep 30, 5:24PM CDT
As the eurozone awaits a key announcement from the European Central Bank, and as the dollar caps its powerful third-quarter advance vs. the euro, Ireland's economy this month reported its Q2 GDP surged 7.7% -- its best performance since 2007. The...
Final Glance: Medical Devices companies
AP - Tue Sep 30, 5:04PM CDT
NEW YORK (AP) — Shares of some top medical devices companies were mixed at the close of trading:
Final Glance: Pharmaceuticals companies
AP - Tue Sep 30, 5:04PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
Stocks Move To Session Lows; Regeneron Rises On Drug Data
at Investor's Business Daily - Tue Sep 30, 2:04PM CDT
Major stock indexes nursed modest losses but were near session lows in late-afternoon trading Tuesday. The Nasdaq and S&P 500 each lost 0.4%, while the Dow Jones industrial average lost 0.3%. NYSE and Nasdaq volume was tracking about 15%-20% higher...
Defective Surgical Product Lawsuits Filed Against Johnson & Johnson
Business Wire - Tue Sep 30, 1:21PM CDT
Johnson & Johnson has been accused of knowingly developing and marketing a defective medical device known as Prolene(R) mesh used in hernia surgery in a series of lawsuits filed in New Jersey Superior Court. The latest, Jacky Pettigrew v. Johnson & Johnson et al., was filed today, according to plaintiffs' co-counsel Theodore J. Leopold of Cohen Milstein Sellers & Toll PLLC.
Midday Glance: Pharmaceuticals companies
AP - Tue Sep 30, 12:20PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Midday Glance: Medical Devices companies
AP - Tue Sep 30, 12:20PM CDT
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 1 p.m.:
Valeant's Bausch + Lomb Announces Results on Lotemax - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 30, 11:10AM CDT
Valeant Pharmaceuticals International, Inc. (VRX) announced that its wholly owned subsidiary, Bausch + Lomb, released positive results from a phase III study on Lotemax.
J&J Buying Alios, Going Up Against Gilead
at Investor's Business Daily - Tue Sep 30, 11:02AM CDT
Medical giant Johnson & Johnson agreed to buy privately held biotech Alios BioPharma for $1.75 billion Tuesday, advancing its presence in viral diseases. Johnson & Johnson (JNJ) stock was up a fraction in morning trading on the stock market today. In...
Early Glance: Medical Devices companies
AP - Tue Sep 30, 9:41AM CDT
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 10 a.m.:
Early Glance: Pharmaceuticals companies
AP - Tue Sep 30, 9:41AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
Johnson & Johnson buying Alios for $1.75B
AP - Tue Sep 30, 9:03AM CDT
NEW BRUNSWICK, N.J. (AP) — Johnson & Johnson is buying the biopharmaceutical company Alios BioPharma Inc. for about $1.75 billion.
Why J&J Expands Antiviral Franchise but Doesn't Buy Achillion, Novavax
at The Street - Tue Sep 30, 8:49AM CDT
What are the motivations behind significant takeovers, like J&J's takeover of Alios Biopharma? And why have companies like Achillion and Novavax been passed over?
How Will Johnson & Johnson (JNJ) Stock Be Affected by This Acquisition?
at The Street - Tue Sep 30, 8:34AM CDT
Johnson & Johnson shares are climbing after the company announced that it acquired Alios BioPharma for $1.75 billion in cash.
Gilead Sciences, Inc. Stock's Stunning New Opportunity
Cheryl Swanson, The Motley Fool - Motley Fool - Tue Sep 30, 8:15AM CDT
Call it Gilead Sciences ' stealth play. Gilead is the king of the HIV business. Its wildly successful Sovaldi launch is without a doubt the biggest biotech event of the year. But the company's experimental cancer drug pipeline is a different...
Cintas Beats on Q1 Earnings with Robust Margin Expansion - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 30, 8:00AM CDT
Cintas (CTAS) reported first-quarter fiscal 2015 adjusted earnings of 78 cents per share versus 62 cents in the year-ago quarter, beating the Zacks Consensus Estimate of 76 cents per share.
Alios BioPharma Announces Acquisition Agreement With Johnson & Johnson
Marketwire - Tue Sep 30, 7:30AM CDT
Alios BioPharma, Inc., a biotechnology company developing proprietary therapeutics for viral diseases, today announced a definitive agreement with Johnson & Johnson whereby Alios will be acquired for approximately $1.75 billion in cash payable upon closing of the transaction. The transaction has been approved by the boards of directors of both companies.
Johnson & Johnson Announces Agreement To Acquire Alios BioPharma
PR Newswire - Tue Sep 30, 7:30AM CDT
Johnson & Johnson (NYSE: JNJ) today announced a definitive agreement to acquire Alios BioPharma, Inc., a privately held clinical stage biopharmaceutical company focused on developing therapies for viral diseases, for approximately $1.75 billion in cash. The acquisition will include Alios BioPharma's portfolio of potential therapeutics for viral infections including compound AL-8176, an orally administered antiviral therapy currently in Phase 2 studies for the treatment of infants with respiratory syncytial virus (RSV).
